A Prospective, Multi-center Clinical Study to Establish Multi-Cancer Early Detection Platform Through the Analysis of Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy Volunteers
Launched by YONSEI UNIVERSITY · Jan 21, 2024
Trial Information
Current as of October 07, 2024
Recruiting
Keywords
Description
AIMA is analysing whole genome sequencing data of circulating tumor DNA, combined through machine learning technique, to develop MCED platform to detect early stage cancer. The purpose of this prospective, multi-center, observational study is to validate an MCED platform for the early detection of cancers. The investigators will collect blood samples from subjects who are diagnosed as invasive cancers before treatment or from healthy volunteers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Aged 19 years or older
- * Subjects who have been diagnosed with stages 1 to 4 of solid tumor or healthy volunteers who have scheduled a cancer screening examination
- * Subjects who have agreed to provide clinical information and blood samples
- * Subjects who have agreed for the storage and secondary use of residual blood samples for research
- * Subjects who have understood the study and are able to provide a written informed consent
- Exclusion Criteria:
- * Subjects who are not appropriate for the study because of intellectual disabilities or severe mental disorders
- * Subjects with a history of HIV, HTLV, or Syphilis infection
- * Subjects with primary site unknown cancer or synchronous or metachronous double primary cancers
- * Subjects who have diagnosed with any other malignant tumor within the past 5 years (except for cured non-melanoma skin cancer, in situ cancer, or thyroid cancer)
About Yonsei University
Yonsei University, a prestigious institution located in South Korea, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Yonsei University leverages its extensive expertise and innovative approaches in various fields of medicine to conduct rigorous clinical trials aimed at improving patient outcomes and advancing healthcare solutions. The university's robust infrastructure, multidisciplinary collaboration, and adherence to ethical standards ensure the integrity and reliability of its research initiatives, making it a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0